DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Grant Opportunity Analysis
The Department of the Army’s USAMRAA is offering the FY26 Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award to support innovative ALS drug or therapy discovery. The award funds hypothesis-driven, high-risk, high-gain research intended to generate preliminary data for future therapeutic investigation, with an emphasis on strong scientific rationale, impact, and mandatory biomarker development; clinical trials are not permitted. Approximately $10.08 million is expected to support about 12 awards, each for up to $840,000 over a two-year period, and eligible applicants include intramural and extramural U.S. Department of War organizations, with principal investigators limited to three applications across ALSRP mechanisms. Applications are submitted in two steps through eBRAP and Grants.gov, with a pre-application due June 24, 2026 and a full application due September 30, 2026.